HOMA-Adiponectin Closely Associates with Cardiometabolic Risk Markers in Middle-Aged Indians with Metabolic Syndrome

Abstract

Background Unhealthy dietary habits and sedentary lifestyles have raised alarming concerns for the rising prevalence of metabolic syndrome (MetS) and associated cardiometabolic risk among Indians at an early age. Insulin resistance and adiposity are the important risk factors associated with MetS. The present study aimed to investigate the relationship between a modified marker of insulin resistance (homeostatic model assessment-adiponectin (HOMA-AD)) and cardiometabolic risk among middle-aged Indians.

Methods The study comprised of 144 subjects of age-group 31–50 years, where 83 subjects were diagnosed for MetS according to the guidelines given by the International Diabetes Federation. We measured cardiometabolic risk indicators such as fasting blood glucose (FPG), fasting plasma insulin (FPI), homeostatic model assessment- insulin resistance (HOMA-IR), adiponectin, high sensitivity C-reactive protein (hs-CRP), oxidized LDL (oxLDL), monocyte chemoattractant protein-1 (MCP-1), and atherogenic index, among others. We calculated HOMA-AD by the formula: [FPG (mmol/l) × FPI (µIU/ml)] / [22.5 × Adiponectin (µg/ml)].

Results HOMA-IR and HOMA-AD were highly increased (p<0.001) in the MetS subjects than controls. Adiponectin was significantly (p<0.01) lower whereas cardiac risk markers such as atherogenic index, hs-CRP, oxLDL, and MCP-1 were significantly (p<0.01) elevated in MetS group than controls. Linear regression showed positive and significant associations (p<0.01) of HOMA-AD with all the cardiometabolic risk markers except MCP-1. HOMA-AD showed higher AUC (0.806) than HOMA-IR (0.791) for predicting MetS.

Conclusion HOMA-AD could be a surrogate adipokine-based marker correlated significantly with components of MetS and cardiometabolic risk indicators. It appeared to be a better predictor of MetS among middle-aged Indians than HOMA-IR.

Key words

adiponectin - cardiometabolic risk - HOMA-AD - insulin resistance - metabolic syndrome - middle-aged

• References

• 1 Wells JC, Pomeroy E, Walimbe SR. et al. The elevated susceptibility to diabetes in India: An evolutionary perspective. Front Public Health 2016; 4: 145
• 2 Engelgau MM, Karan A, Mahal A. The economic impact of non-communicable diseases on households in India. Global Health 2012; 8: 9
• 3 Chauhan S, Aeri BT. Prevalence of cardiovascular disease in India and its economic impact-A review. Int J Sci Res Publ 2013; 3: 1-5
• 4 The IDF consensus worldwide definition of the metabolic syndrome. Available from: http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf; [Last accessed on 2019 June 28]
• 5 Enas EA, Mohan V, Deepa M. et al. The metabolic syndrome and dyslipidemia among Asian Indians: A population with high rates of diabetes and premature coronary artery disease. J Cardiometab Syndr 2007; 2: 267-275
• 6 Bhatti GK, Bhadada SK, Vijayvergiya R. et al. Metabolic syndrome and risk of major coronary events among the urban diabetic patients: North Indian Diabetes and cardiovascular disease study — NIDCVD-2. J Diabetes Complications 2016; 30: 72-78
• 7 Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab 2009; 296: E581-E591
• 8 Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol 2016; 12: 144
• 9 Cho SA, Joo HJ, Cho JY. et al. Visceral fat area and serum adiponectin level predict the development of metabolic syndrome in a community-based asymptomatic population. PLoS One 2017; 12: e0169289
• 10 Yoon CY, Kim YL, Han SH. et al. Hypoadiponectinemia and the presence of metabolic syndrome in patients with chronic kidney disease: Results from the KNOW-CKD study. Diabetol Metab Syndr 2016; 8: 75
• 11 Timar R, Timar B, Degeratu D. et al. Metabolic syndrome, adiponectin and proinflammatory status in patients with type 1 diabetes mellitus. J Int Med Res 2014; 42: 1131-1138
• 12 Yadav A, Kataria MA, Saini V. et al. Role of leptin and adiponectin in insulin resistance. Clin Chim Acta 2013; 417: 80-84
• 13 Kurinami N, Sugiyama S, Yoshida A. et al. Correlation of body muscle/fat ratio with insulin sensitivity using hyperinsulinemic-euglycemic clamp in treatment-naïve type 2 diabetes mellitus. Diabetes Res Clin Pract 2016; 120: 65-72
• 14 Mcmullan BC, Akwo EA, Hung AM. Performance of Insulin Sensitivity Indices vs. the Hyperinsulinemic Euglycemic Clamp in Chronic Kidney Disease. Diabetes 2019; 68 (Supp 1) 1657-P
• 15 Vilela BS, Vasques AC, Cassani RS. et al. Homa-adiponectin index as useful surrogate marker in the screeening of insulin resistance. Diabetol Metab Syndr 2015; 7: A135
• 16 Makni E, Moalla W, Lac G. et al. The Homeostasis Model Assessment-adiponectin (HOMA-AD) is the most sensitive predictor of insulin resistance in obese children. Ann Endocrinol 2012; 73: 26-33
• 17 Hung AM, Sundell MB, Egbert P. et al. A comparison of novel and commonly-used indices of insulin sensitivity in African American chronic hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 767-774
• 18 Kizer JR. Adiponectin, cardiovascular disease, and mortality: Parsing the dual prognostic implications of a complex adipokine. Metab Clin Exp 2014; 63: 1079-1083
• 19 Sharma S, Colangelo LA, Lloyd-Jones D. et al. Longitudinal associations between adiponectin and cardiac structure differ by hypertensive status: Coronary Artery Risk Development in Young Adults. Cardiovasc Endocrinol 2016; 5: 57
• 20 Misra A, Chowbey P, Makkar BM. et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. JAPI 2009; 57: 163-170
• 21 American Diabetes Association 2. Classification and diagnosis of diabetes. Diabetes Care 2017; 40 (Supplement 1) S11-S24
• 22 Matthews DR, Hosker JP, Rudenski AS. et al. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
• 23 Dobiášová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apob-lipoprotein-depleted plasma (FERHDL). Clin Biochem 2001; 34: 583-588
• 24 Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. John Wiley & Sons, Inc; 2000: 156-164
• 25 Gradinaru D, Margina D, Borsa C. et al. Adiponectin: possible link between metabolic stress and oxidative stress in the elderly. Aging Clin Exp Res 2017; 29: 621-629
• 26 Nigro E, Scudiero O, Monaco ML. et al. New insight into adiponectin role in obesity and obesity-related diseases. Biomed Res Int 2014; 2014: 658913
• 27 Zhang H, Cui J, Zhang C. Emerging role of adipokines as mediators in atherosclerosis. World J Cardiol 2010; 2: 370
• 28 Kou H, Deng J, Gao D. et al. Relationship among adiponectin, insulin resistance and atherosclerosis in non-diabetic hypertensive patients and healthy adults. Clin Exp Hypertens 2018; 40: 656-663
• 29 Hu LT, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct Equ Modeling 1999; 6: 1-55
• 30 Liu Z, Liang S, Que S. et al. Meta-analysis of adiponectin as a biomarker for the detection of metabolic syndrome. Front Physiol 2018; 9: 1238
• 31 Xu A, Vanhoutte PM. Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am J Physiol Heart Circ Physiol 2011; 302: H1231-H1240
• 32 Matsuhisa M, Yamasaki Y, Emoto M. et al. A novel index of insulin resistance determined from the homeostasis model assessment index and adiponectin levels in Japanese subjects. Diabetes Res Clin Pract 2007; 77: 151-154
• 33 Vilela BS, Vasques AC, Cassani RS. et al. The HOMA-adiponectin (HOMA-AD) closely mirrors the HOMA-IR index in the screening of insulin resistance in the Brazilian metabolic syndrome study (BRAMS). PloS One 2016; 11: e0158751
• 34 da Silva CD, Zambon MP, Vasques AC. et al. Homeostatic model assessment of adiponectin (HOMA-Adiponectin) as a surrogate measure of insulin resistance in adolescents: Comparison with the hyperglycaemic clamp and homeostatic model assessment of insulin resistance. PloS One 2019; 14: e0214081
• 35 Vicente SE, Corgosinho FC, da Silveira Campos RM. et al. The impact of adiponectin levels on biomarkers of inflammation among adolescents with obesity. Obes Med 2017; 5: 4-10
• 36 Nwagha UI, Igwe J. Atherogenic Index of Plasma: A significant indicator for the onset of Atherosclerosis during menopause in hypertensive females of South East Nigeria. Int J Med Health Dev 2005; 10: 67-71
• 37 Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm 2013; 2013: 152786